Oscar Health, Inc. is a healthcare technology company that offers health insurance plans through the Affordable Care Act (ACA) marketplaces for individuals, families, and employees. The company operates a full-stack technology platform that powers its insurance business and provides tools to providers and payors through the +Oscar platform, which includes Campaign Builder for engagement and recommendations. Oscar offers health plans in five metal categories (Catastrophic, Bronze, Silver, Gold, and Platinum) with specific products targeting conditions such as diabetes, asthma, and menopause. The company serves customers in 18 states for the 2025 policy year, expanding to 20 states for 2026, with significant membership in Florida, Texas, and Georgia. In 2025, Oscar acquired Lucie, Inc., IHC Specialty Benefits, Inc., and Healthinsurance.org, LLC to support its Individual Coverage Health Reimbursement Arrangements (ICHRA) strategy and brokerage services. The company partners with health systems and providers, including Cleveland Clinic, and previously maintained a co-branded partnership with Cigna for small group plans, which ended in 2024. Founded in 2012, Oscar focuses on member experience, clinical care, and transparent pricing.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Healthcare Plans Homepage hioscar.com
Sector Healthcare IR page ir.oscarhealth.com
Tags
health insurance, aca marketplace, ichra, healthcare technology, member engagement, clinical care, brokerage services, enrollment platform, predictive analytics, individual market, +Oscar, Campaign Builder, Lucie Inc., IHC Specialty Benefits Inc., Healthinsurance.org LLC, Cigna+Oscar, Cleveland Clinic
Press page —

Metrics

Valuation  
Market cap $ 10.685B
Market cap (USD) $ 10.685B
P/E 12.49
PEG —
P/BV 4.81
P/S 394.66
P/OCF 2.55
P/FCF 2.58
Dividend yield —
Turnover / mcap —
Returns  
ROE -44.5%
ROI -31.5%
ROIC -21.1%
Profit margin -1,549.9%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 19.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 29
Quality score -29.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 28.593M 20.576M 15.442M 61.047M 1.839B 0
Net profit -443.151M 25.432M -270.728M -606.275M -572.606M 0
Free cash flow 1.058B 950.296M -297.736M 351.337M -207.63M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 14.37 13.44 9.15 2.46 7.85 —
Price performance 12m 0.07 0.47 2.72 -0.69 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — — — 363M
Borrowings, non-current (USD) — — 142M 0.00 298M 299M 300M 430M
Lease liabilities (USD) — — — 91.7B 85M 81M 74.2M 68.7M
Cash and deposits (USD) 370M 353M 826M 1.1B 1.56B 1.87B 1.53B 2.77B
Right-of-use assets (USD) — — — 73B 68M 62.9M 57.2M 51.5M
Net debt (borrowings + leases - cash) (USD) — — -684M 90.6B -1.18B -1.49B -1.15B -2.28B
Cash flow detail
Operating cash flow (USD) — -165M 223M -182M 380M -272M 978M 1.09B
Purchases of property, plant and equipment (USD) — -26M -14M -25.9M -29M -25.6M -27.9M -36.4M
Change in payables (cash effect) (USD) — 7.51M 75.8M 98.6M 57.8M -29.2M 153M 205M
Share buybacks (cash effect) (USD) — -2.99M 0.00 0.00 — — — —
Interest paid (cash effect) (USD) — 0.00 0.00 -4.26M -10.1M -23.2M -33.7M -12.8M
Income taxes paid (cash effect) (USD) — -1.83M -1.53M -697,000 -1.89M -2.41M -674,000 -17.5M
Share-based compensation (USD) — 33.6M 35.9M 86.3M 112M 160M 110M 87.7M
Free cash flow (OCF - PPE - intangibles) (USD) — -191M 209M -208M 351M -298M 950M 1.06B
Income detail
Total comprehensive income (USD) — -261M -406M -576M -616M -260M 23M -423M
Comprehensive income to owners (USD) — -261M -406M -577M -612M -260M 22.3M -423M
Reported Feb 25, 2022 Feb 25, 2022 Feb 25, 2022 Feb 25, 2022 Feb 24, 2023 Feb 15, 2024 Feb 20, 2025 May 7, 2026

Operating KPIs — quarters

KPI Dec 24 Mar 25 Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 Sep 26
Customers 1.68M 2.04M 2.03M 2.12M 2.04M 3.17M 2.96M 2.69M
↳ YoY growth +61.8% +40.8% +28.2% +28.0% +21.8% +55.7% +46.2% +27.2%
Reported Feb 4, 2025 May 7, 2025 Aug 6, 2025 Nov 6, 2025 Feb 10, 2026 May 6, 2026 Aug 6, 2026 Nov 5, 2026

Operating KPIs — years

KPI Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Customers 402,044 598,169 1.15M 1.04M 1.68M 2.04M
↳ YoY growth +48.8% +92.5% -10.0% +61.8% +21.8%
Reported Feb 10, 2022 Feb 10, 2022 Feb 9, 2023 Feb 7, 2024 Feb 4, 2025 Feb 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 12, 2026, the Board of Directors (the “Board”) of Oscar Health, Inc. (the “Company”) appointed Messrs. Tomer Cohen, Eric Larsen, and Rajat Taneja to the Board, effective November 13, 2026 (the “Effective Date”), and increased the size of the Board from eight to eleven directors in connection therewith. Each director will serve for a term expiring at the Company’s annual meeting of stockholders to be held in 2027 and until his successor is duly elected and qualified or until his earlier death, disqualification, resignation or removal. Mr. Cohen was also appointed as a member of the Talent and Compensation Committee of the Board (the “Compensation Committee”), and Mr. Taneja was appointed as a member of the Audit Committee and the Nominating and Corporate Governance Committee (the “NCG Committee”), in each case effective as of the Effective Date. The Board determined that each of Messrs. Cohen, Larsen, and Taneja qualifies as independent under the rules of the New York Stock Exchange, including, in Mr.

ir.oscarhealth.com Bull 6 Bear 0 Results

News Release

Oscar Health Announces Financial Results for Third Quarter 2026 and Raises Full Year 2026 Outlook

New York, NY, November 5, 2026 – Oscar Health, Inc. (“Oscar Health” or the “Company”) (NYSE: OSCR) announced today its financial results for the third quarter ended September 30, 2026, and updates to its full year 2026 outlook.

“Oscar Health is on track to deliver the strongest year of financial performance in our history, and we are raising our earnings from operations outlook for a third time,” said Mark Bertolini, CEO of Oscar Health. “The ACA is the foundation of a rapidly-developing individual market in America, and Oscar Health is built to lead it.

November 05, 2026 6:00am EST Download as PDF

Related Documents

Earnings WebcastAudio Q3 2026

10-QHTML Q3 2026 PDF XBRL Zip

NEW YORK--(BUSINESS WIRE)-- Oscar Health, Inc. (“Oscar Health” or the “Company”) (NYSE: OSCR) announced today its financial results for the third quarter ended September 30, 2026, and updates to its full year 2026 outlook.

“Oscar Health is on track to deliver the strongest year of financial performance in our history, and we are raising our earnings from operations outlook for a third time,” said Mark Bertolini, CEO of Oscar Health. “The ACA is the foundation of a rapidly-developing individual market in America, and Oscar Health is built to lead it. Our disciplined pricing, consumer-led products, and technology-powered approach are driving stronger economics and position us to grow market share and expand margin in 2027.”

Third Quarter 2026 Financial Highlights

Scroll to view ↔

Three Months Ended September 30, Nine Months Ended September 30,
(in thousands, except percentages) 2026 2025 2026 2025
Total revenue $5,139,298 $2,985,984 $14,666,712 $8,896,192
Medical loss ratio (“MLR”) 84.0% 88.5% 78.1% 84.8%
Selling, general, and administrative (“SG&A”) expense ratio 14.0% 17.5% 14.4% 17.3%
Earnings (loss) from operations $178,018 $(129,250) $1,270,738 $(62,610)
Net income (loss) attributable to Oscar Health, Inc. $167,281 $(137,450) $1,208,085 $(90,540)
Adjusted EBITDA (1) $206,852 $(101,453) $1,349,273 $27,971
(1) Adjusted EBITDA is a non-GAAP measure. See “Key Operating and Non-GAAP Financial Metrics - Adjusted EBITDA” in this release for a reconciliation to net income, the most directly comparable GAAP measure, and for information regarding Oscar Health’s use of Adjusted EBITDA.

Scroll to view ↔

As of September 30,
Effectuated Membership by Offering 2026 2025
Individual and Small Group (1) 2,691,885 2,111,736
Cigna+Oscar (2) — 5,168
Total Members (3) 2,691,885 2,116,904
(1) Membership includes members enrolled through a Custom Health Option and Individual Care Expense Arrangement (“CHOICE”). 2025 membership includes small group members. The Company no longer offers small group plans effective December 15, 2024.
(2) Represents total membership for our former co-branded partnership with Cigna. We did not renew the Cigna+Oscar Small Group arrangement after its initial term ended on December 31, 2024.
(3) Represents effectuated members. Effectuated members are those who are actively enrolled in one of our plans and whose required premium payments have either been made or are within the payment grace period. A member covered under more than one of our health plans counts as a single member for the purposes of this metric.

Scroll to view ↔

2026 Financial Guidance Summary
Prior Full Year 2026 Outlook Updated Full Year 2026 Outlook
(in thousands, except percentages) Low High Low High
Total revenue (1) $18.7 billion $19.0 billion $19.0 billion $19.3 billion
Medical loss ratio (2) 81.0% 82.0% 80.5% 81.5%
SG&A expense ratio (3) 15.6% 16.1% 15.1% 15.6%
Earnings from operations (4) $600 million $800 million $850 million $950 million
(1) Total revenue includes premium revenue (net of risk adjustment transfers), investment income, and other revenue. We believe total revenue is an important metric to assess the growth of our business, as well as the earnings potential of our investment portfolio.
(2) Medical loss ratio (MLR) is a metric used to calculate medical expenses as a percentage of net premiums before ceded quota share reinsurance. We believe MLR is an important metric to demonstrate the ratio of our costs to pay for the healthcare of our members to the net premiums before ceded quota share reinsurance.
(3) Selling, general, and administrative (SG&A) expense ratio is calculated as selling, general and administrative expenses as a percentage of total revenue (net of risk adjustment transfers). We believe the SG&A expense ratio is useful to evaluate our ability to manage our overall selling, general, and administrative cost base.
(4) Earnings from operations is the Company's total revenue less total operating expenses. We believe earnings from operations is an important primary metric for assessing operating performance.

Third Quarter 2026 Key Metrics and Non-GAAP Financial Metrics

  • Total revenue was approximately $5.1 billion for the third quarter of 2026 compared to $3.0 billion for the third quarter of 2025. The increase was driven by rate increases and higher membership. Revenue for the third quarter of 2026 included a $250 million benefit from updated risk adjustment estimates, driven by favorable development in the Company’s risk scores relative to the market and modestly favorable market morbidity relative to expectations.
  • The medical loss ratio was 84.0% for the third quarter of 2026 compared to 88.5% for the third quarter of 2025. The decrease was primarily driven by our disciplined pricing strategy. The Company had $42 million of favorable prior period development in the third quarter of 2026 compared to $84 million of favorable prior period development in the third quarter of 2025.
  • The SG&A expense ratio was 14.0% for the third quarter of 2026 compared to 17.5% for the third quarter of 2025. The decrease was primarily due to lower risk adjustment as a percentage of premium, greater fixed cost leverage, and disciplined expense management.
  • Earnings from operations were $178.0 million for the third quarter of 2026 compared to a loss from operations of $129.3 million for the third quarter of 2025. The significant increase reflects strong operating performance driven primarily by improved underwriting performance.
  • Net income attributable to Oscar Health, Inc. was $167.3 million, or $0.49 of diluted earnings per share, for the third quarter of 2026 compared to net loss attributable to Oscar Health, Inc. of $137.5 million, or $(0.53) of diluted loss per share, for the third quarter of 2025.
  • Adjusted EBITDA was $206.9 million for the third quarter of 2026 compared to an adjusted EBITDA loss of $101.5 million for the third quarter of 2025.

Quarterly Conference Call Details

Oscar Health will host a conference call to discuss its financial results today, November 5, 2026, at 8:00 a.m. (ET). A live audio webcast will be available online via the Investor Relations page of Oscar Health’s website at ir.oscarhealth.com . A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

Non-GAAP Financial Information

This release presents adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). A reconciliation of historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release. For more information regarding adjusted EBITDA, please see “Key Operating and Non-GAAP Financial Metrics” below.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained herein are forward-looking statements. These statements include, but are not limited to, statements about our financial outlook and estimates, including Total revenue, Medical loss ratio, SG&A expense ratio, Earnings (loss) from operations, and other financial performance metrics, and the related underlying assumptions, our business and financial prospects, including management’s plans and objectives for future operations, expectations and business strategy, such as our margins, market share and profitability, and industry and market dynamics and expected trends. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “forecasts,” “predicts,” “potential,” or “continues” or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict and generally beyond our control.

Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, there are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our ability to execute our strategy and manage our growth effectively (including our ability to successfully integrate strategic acquisitions); our ability to retain and expand our member base; our ability to accurately estimate our incurred medical expenses or overall market morbidity, or effectively manage our medical costs or related administrative costs; unanticipated results of, or changes to, risk adjustment programs or our estimates thereof; evolving federal or state laws or regulations (including any changes in the interpretation or enforcement of existing laws and regulations), including changes with respect to the Patient Protection and Affordable Care Act (“ACA”) and any regulations enacted thereunder, the expiration of the enhanced Advanced Premium Tax Credits, the implementation of new program integrity rules, such as ID proofing rules, and rules pursuant to the Notice of Benefit and Payment Parameters for policy year 2027, the potential funding of a cost-sharing reduction program, or other government actions, such as the imposition of tariffs; our ability to achieve or maintain profitability in the future; our ability to arrange for the delivery of quality care and maintain good relations with brokers and the physicians, hospitals, and other providers within and outside our provider networks; our ability to comply with ongoing, complex and evolving regulatory requirements, including capital reserve and surplus requirements and applicable performance standards; changes or developments in the regulation of health insurance markets in the United States; our, or any of our vendors’, ability to comply with laws, regulations, and standards related to the handling of information about individuals or applicable consumer protection laws, including as a result of our participation in government-sponsored programs; the ability of our health insurance and Health Maintenance Organization subsidiaries to make payments of dividends or distributions to us, including to fund our business strategy; our ability to utilize quota share reinsurance to meet our capital and surplus requirements and protect against downside risk on medical claims; adverse market conditions resulting in our investment portfolio suffering losses or reducing our ability to meet our financing needs; unfavorable or otherwise costly outcomes of lawsuits, audits, investigations, and other third party claims that may arise from the extensive laws and regulations to which we are subject, such as fraud, waste and abuse laws; incurrence of data security breaches of our or our partners’ information and technology systems; heightened competition in the markets in which we participate; our ability to attract and retain qualified personnel; uncertainties associated with our utilization of certain artificial intelligence and machine learning models; our ability to detect and prevent material weaknesses or significant control deficiencies in our internal controls over financial reporting or other failure to maintain an effective system of internal controls; adverse publicity or other adverse consequences related to our dual class structure or “controlled company” status; and the other factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”), and our other filings with the SEC.

You are cautioned not to place undue reliance on any forward-looking statements made in this press release. Any forward-looking statement speaks only as of the date as of which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise.

About Oscar Health

Oscar Health, Inc. (NYSE: OSCR) is a leading consumer healthcare company that gives people power over their healthcare. Oscar Health serves millions of consumers, employers, brokers, and partners through Oscar Insurance, Lucie Health Marketplace, and Trove Group. Together these businesses deliver exceptional lifestyle products and technology platforms that make healthcare easy to choose, use, and experience. Learn more at OscarHealth.com .

Scroll to view ↔

Oscar Health, Inc.Condensed Consolidated Statements of Operations(unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
(in thousands, except per share amounts) 2026 2025 2026 2025
Revenue
Premium $ 5,041,987 $ 2,923,968 $ 14,412,180 $ 8,723,233
Investment income 91,016 53,215 236,424 153,331
Other revenues 6,295 8,801 18,108 19,628
Total revenue 5,139,298 2,985,984 14,666,712 8,896,192
Operating Expenses
Medical 4,232,845 2,586,330 11,257,147 7,398,954
Selling, general, and administrative 721,892 521,592 2,119,206 1,538,836
Depreciation and amortization 6,543 7,312 19,621 21,012
Total operating expenses 4,961,280 3,115,234 13,395,974 8,958,802
Earnings (loss) from operations 178,018 (129,250 ) 1,270,738 (62,610 )
Interest expense 4,726 6,857 14,818 18,698
Other expenses (income) (2,089 ) 3,184 (1,245 ) 3,308
Earnings (loss) before income taxes 175,381 (139,291 ) 1,257,165 (84,616 )
Income tax expense (benefit) 8,077 (1,807 ) 49,010 5,853
Net income (loss) 167,304 (137,484 ) 1,208,155 (90,469 )
Less: Net income (loss) attributable to noncontrolling interests 23 (34 ) 70 71
Net income (loss) attributable to Oscar Health, Inc. $ 167,281 $ (137,450 ) $ 1,208,085 $ (90,540 )
Earnings (loss) per Share
Basic $ 0.54 $ (0.53 ) $ 3.98 $ (0.35 )
Diluted $ 0.49 $ (0.53 ) $ 3.59 $ (0.35 )
Weighted Average Common Shares Outstanding
Basic 309,339 259,273 303,259 255,419
Diluted 346,457 259,273 339,281 255,419

Scroll to view ↔

Oscar Health, Inc.Condensed Consolidated Balance Sheets(unaudited)
(in thousands, except per share amounts) September 30, 2026 December 31, 2025
Assets
Current Assets:
Cash and cash equivalents $ 4,466,858 $ 2,774,151
Short-term investments 3,021,732 1,216,461
Accounts receivable (net of allowance for credit losses of $19,131 and $7,226) 303,302 362,682
Reinsurance recoverable 270,643 99,750
Receivables from CMS 193,793 136,029
Other current assets 59,831 24,331
Total current assets 8,316,159 4,613,404
Long-term investments 1,441,909 1,470,987
Property, equipment, and capitalized software, net 109,312 88,350
Restricted deposits 27,484 32,951
Other assets 114,116 119,719
Total assets $ 10,008,980 $ 6,325,411
Liabilities and Stockholders' Equity
Current Liabilities:
Payables to CMS $ 4,626,054 $ 2,730,095
Benefits payable 1,924,075 1,455,385
Accounts payable and other liabilities 589,220 507,325
Unearned premiums 160,392 166,203
Reinsurance payable 1,711 3,579
Total current liabilities 7,301,452 4,862,587
Long-term debt 432,410 430,095
Other liabilities 49,324 51,994
Total liabilities 7,783,186 5,344,676
Commitments and contingencies
Stockholders' Equity
Class A common stock ($0.00001 par value; 825,000 thousand shares authorized, 275,454 thousand and 261,851 thousand shares outstanding as of September 30, 2026 and December 31, 2025, respectively) 3 3
Class B common stock ($0.00001 par value; 82,500 thousand shares authorized, 35,176 thousand and 35,838 thousand shares outstanding as of September 30, 2026 and December 31, 2025, respectively) — —
Treasury stock (315 thousand shares as of September 30, 2026 and December 31, 2025) (2,923 ) (2,923 )
Additional paid-in capital 4,353,570 4,256,972
Accumulated deficit (2,086,349 ) (3,294,434 )
Accumulated other comprehensive income (loss) (41,664 ) 18,030
Total Oscar Health, Inc. stockholders' equity 2,222,637 977,648
Noncontrolling interests 3,157 3,087
Total stockholders' equity 2,225,794 980,735
Total liabilities and stockholders' equity $ 10,008,980 $ 6,325,411

Scroll to view ↔

Oscar Health, Inc.Condensed Consolidated Statements of Cash Flows(unaudited)
Nine Months Ended September 30,
(in thousands) 2026 2025
Cash Flows from Operating Activities:
Net income (loss) $ 1,208,155 $ (90,469 )
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Change in provision for credit losses 11,905 (24,020 )
Stock-based compensation expense 58,914 69,569
Depreciation and amortization expense 19,592 21,012
Amortization of debt issuance costs 3,339 774
Net accretion of investments (22,975 ) (23,066 )
Deferred taxes (4,313 ) (175 )
Net realized gain on sale of financial instruments (1,907 ) (1,302 )
Changes in assets and liabilities:
(Increase) / decrease in:
Reinsurance recoverable (170,893 ) 132,146
Accounts receivable 47,474 (54,402 )
Receivables from CMS (57,764 ) (78,240 )
Other assets (21,608 ) (29,759 )
Increase / (decrease) in:
Payables to CMS 1,895,959 266,501
Benefits payable 468,691 207,665
Accounts payable and other liabilities 83,847 58,061
Unearned premiums (5,811 ) 2,727
Reinsurance payable (1,868 ) (34,071 )
Net cash provided by operating activities 3,510,737 422,951
Cash Flows from Investing Activities:
Sale of investments 1,149,495 134,231
Maturity and paydowns of investments 1,614,749 478,173
Change in restricted deposits 211 3,225
Purchase of investments (4,578,517 ) (780,673 )
Purchase of property, equipment, and capitalized software (31,864 ) (27,310 )
Net cash used in investing activities (1,845,926 ) (192,354 )
Cash Flows from Financing Activities:
Proceeds from long-term debt — 410,000
Proceeds from exercise of stock options and stock purchase agreement 41,828 42,192
Tax payments related to net settlement of share-based awards (11,920 ) (4,035 )
Purchase of capped calls related to convertible notes — (34,440 )
Payments of debt issuance costs (5,990 ) (22,677 )
Earn-out liability payout (3,370 ) —
Net cash provided by financing activities 20,548 391,040
Increase in cash, cash equivalents and restricted cash equivalents 1,685,359 621,637
Cash, cash equivalents, restricted cash and cash equivalents—beginning of period 2,804,123 1,551,118
Cash, cash equivalents, restricted cash and cash equivalents—end of period 4,489,482 2,172,755
Cash and cash equivalents 4,466,858 2,148,865
Restricted cash and cash equivalents included in restricted deposits 22,624 23,890
Total cash, cash equivalents and restricted cash and cash equivalents $ 4,489,482 $ 2,172,755
Supplemental Disclosures:
Interest payments $ 10,612 $ 11,515
Income tax payments $ 1,438 $ 17,497

Key Operating and Non-GAAP Financial Metrics

We regularly review the following key operating and Non-GAAP financial metrics, to evaluate our business, measure our performance, identify trends in our business, prepare financial projections, and make strategic decisions. We believe these operational and financial measures are useful in evaluating our performance, in addition to our financial results prepared in accordance with GAAP.

Total Revenue

Total revenue includes premium revenue (net of risk adjustment transfers), investment income, and other revenues. We believe total revenue is an important metric to assess the growth of our business, as well as the earnings potential of our investment portfolio.

MLR

MLR is a metric used to calculate medical expenses as a percentage of net premiums before ceded quota share reinsurance. The impact of the federal risk adjustment program is included in the denominator of our MLR. We believe MLR is an important metric to demonstrate the ratio of our costs to pay for healthcare of our members to the net premium before ceded quota share reinsurance.

Scroll to view ↔

Three Months Ended September 30, Nine Months Ended September 30,
(in thousands, except percentages) 2026 2025 2026 2025
Net claims before ceded quota share reinsurance (A) $ 4,232,845 $ 2,586,330 $ 11,257,147 $ 7,398,954
Net premiums before ceded quota share reinsurance (B) $ 5,041,987 $ 2,923,968 $ 14,412,180 $ 8,723,233
Medical Loss Ratio (A divided by B) 84.0 % 88.5 % 78.1 % 84.8 %

SG&A Expense Ratio

The SG&A expense ratio reflects the Company’s selling, general, and administrative expenses, as a percentage of total revenue (net of risk adjustment transfers). We believe the SG&A expense ratio is useful to evaluate our ability to manage our overall selling, general, and administrative cost base.

Earnings (Loss) from Operations

Earnings (loss) from operations is the Company's total revenue less total operating expenses. We believe earnings (loss) from operations is an important primary metric for assessing operating performance.

Net Income (Loss) Attributable to Oscar Health, Inc.

Net income (loss) attributable to Oscar Health, Inc. is net earnings (loss) allocated to the Company after net income (loss) attributable to noncontrolling interests. It is a key indicator of the Company’s profitability and operational efficiency, allowing management to evaluate performance and make informed decisions on strategic planning, cost management, and resource allocation.

Adjusted EBITDA

Adjusted EBITDA is defined as Net income (loss) for the Company and its consolidated subsidiaries before interest expense, income tax expense (benefit), and depreciation and amortization, as further adjusted for stock-based compensation and other items that are considered unusual or not representative of underlying trends of our business, where applicable for the period presented. We present Adjusted EBITDA because we believe it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Adjusted EBITDA is a non-GAAP measure. Management believes that investors’ understanding of our performance is enhanced by including this non-GAAP financial measure as a reasonable basis for comparing our ongoing results of operations. We caution investors that amounts presented in accordance with our definition of Adjusted EBITDA may not be comparable to similar measures disclosed by our competitors, because not all companies and analysts calculate Adjusted EBITDA in the same manner.

By providing this non-GAAP financial measure, together with a reconciliation to the most comparable U.S. GAAP measure, Net income (loss), we believe we are enhancing investors’ understanding of our business and our results of operations, as well as assisting investors in evaluating how well we are executing our strategic initiatives. Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation, or as an alternative to, or a substitute for, net income (loss) or other financial statement data presented in our Condensed Consolidated Financial Statements as indicators of financial performance.

Scroll to view ↔

Three Months Ended September 30, Nine Months Ended September 30,
(in thousands) 2026 2025 2026 2025
Net income (loss) $ 167,304 $ (137,484 ) $ 1,208,155 $ (90,469 )
Interest expense 4,726 6,857 14,818 18,698
Other expenses (income) (2,089 ) 3,184 (1,245 ) 3,308
Income tax expense (benefit) 8,077 (1,807 ) 49,010 5,853
Earnings (loss) from operations 178,018 (129,250 ) 1,270,738 (62,610 )
Depreciation and amortization 6,543 7,312 19,621 21,012
Stock-based compensation (1) 22,291 20,485 58,914 69,569
Adjusted EBITDA $ 206,852 $ (101,453 ) $ 1,349,273 $ 27,971
(1) Represents non-cash expenses related to equity-based compensation programs, which vary from period to period depending on various factors including the timing, number, and the valuation of awards. Additionally, these expenses are reported net of any stock-based compensation that has been capitalized for software development costs.

Appendix

Supplemental Financial Information

Premium

The Company records premium revenue net of premiums for reinsurance contracts accounted for under reinsurance accounting. The following table reconciles total reinsurance premiums ceded and reinsurance premiums assumed, which are included as components of total premium revenue in the Condensed Consolidated Statements of Operations:

Scroll to view ↔

Three Months Ended September 30, Nine Months Ended September 30,
(in thousands) 2026 2025 2026 2025
Direct policy premiums $ 5,724,382 $ 3,646,308 $ 17,421,126 $ 10,478,743
Risk adjustment transfers (677,299 ) (727,538 ) (2,991,580 ) (1,793,532 )
Reinsurance premiums ceded (5,133 ) (3,048 ) (15,740 ) (8,280 )
Assumed premiums (1) 37 8,246 (1,626 ) 46,302
Premium $ 5,041,987 $ 2,923,968 $ 14,412,180 $ 8,723,233
(1) The Company did not renew the Cigna+Oscar Small Group arrangement with Cigna Health and Life Insurance Company after its initial term ended on December 31, 2024. Following termination, the Company has been providing transition and run-off services, and will continue to provide such services through December 31, 2026. The Company also continues to share in premiums and claims for plans sold or issued prior to December 15, 2024.

Medical Expenses

The Company records medical expenses net of reinsurance recoveries for reinsurance contracts accounted for under reinsurance accounting. The following table reconciles total medical expenses to the amount presented in the Condensed Consolidated Statements of Operations:

Scroll to view ↔

Three Months Ended September 30, Nine Months Ended September 30,
(in thousands) 2026 2025 2026 2025
Direct claims incurred $ 4,308,064 $ 2,626,830 $ 11,474,762 $ 7,457,231
Ceded reinsurance claims (76,116 ) (47,750 ) (217,190 ) (100,965 )
Assumed reinsurance claims 897 7,250 (425 ) 42,688
Medical expenses $ 4,232,845 $ 2,586,330 $ 11,257,147 $ 7,398,954

Risk Adjustment

The risk adjustment programs in the markets the Company serves are administered federally by CMS and are designed to mitigate the potential impact of adverse selection and provide stability for health insurers. Under these programs, each plan is assigned a risk score based upon demographic information and current year claims information related to its members. Plans with lower than average risk scores generally pay into the pool, while plans with higher than average risk scores generally receive distributions. The following table provides a rollforward of the Company’s beginning and ending risk adjustment receivable and payable balances for the nine months ended September 30, 2026 and 2025:

Scroll to view ↔

Nine Months Ended September 30, 2026 Nine Months Ended September 30, 2025
(in thousands) Risk Adjustment Receivable Risk Adjustment Payable Net Risk Adjustment Payable Risk Adjustment Receivable Risk Adjustment Payable Net Risk Adjustment Payable
Beginning balance (1) $ 56,066 $ 2,587,700 $ 2,531,634 $ 64,779 $ 1,558,341 $ 1,493,562
Change in accrual:
Current year $ 45,482 $ 3,095,693 $ 3,050,211 $ 41,983 $ 1,759,485 $ 1,717,502
Prior years 56,371 (2,028 ) (58,399 ) 16,595 92,626 76,031
Change in accrual, net $ 101,853 $ 3,093,665 $ 2,991,812 $ 58,578 $ 1,852,111 $ 1,793,533
Payments:
Prior years $ 27,088 $ 2,555,975 $ 2,528,887 $ 30,776 $ 1,639,147 $ 1,608,371
Payments $ 27,088 $ 2,555,975 $ 2,528,887 $ 30,776 $ 1,639,147 $ 1,608,371
Ending balance:
Current year $ 45,482 $ 3,095,693 $ 3,050,211 $ 41,983 $ 1,759,485 $ 1,717,502
Prior years 85,349 29,697 (55,652 ) 50,598 11,820 (38,778 )
Ending balance $ 130,831 $ 3,125,390 $ 2,994,559 $ 92,581 $ 1,771,305 $ 1,678,724
(1) The table includes risk adjustment data validation (“RADV”) receivables and payables. The balance at the beginning of each year presented pertains to prior policy years.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261105823197/en/

Investor Contact:
Chris Potochar
VP of Investor Relations
[email protected]

Media Contact:
Dalya Browne
Senior Director, External Communications
[email protected]

Source: Oscar Health, Inc.

Released November 5, 2026

©2026 Oscar Health, Inc. All Rights Reserved.

Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .

Prompts

Oscar Health, Inc. (ticker OSCR), listed in United States.

Company History

Date Change Detail
Dec 7, 2020 Renamed Mulberry Health Inc. → OSCAR HEALTH, INC.

ETFs Holding Oscar Health, Inc.

ETF Weight in ETF Shares Market value As of
CTEF 4.33% 847,643 $ 25.29M Nov 18, 2026
HYP 3.13% 75,880 $ 2.164M Jun 30, 2026
TCV 2.48% 165,188 $ 4.93M Nov 18, 2026
RNIN 1.19% 83,538 $ 2.49M Nov 18, 2026
DSMC 0.92% 41,442 $ 1.182M Jun 30, 2026
FSEG 0.74% 1,477 $ 42.124K Jun 30, 2026
JSML 0.60% 69,666 $ 2.175M Jul 31, 2026
LITL 0.53% 1,015 $ 30.288K Nov 17, 2026
JSMD 0.51% 171,181 $ 5.344M Jul 31, 2026
AVUV 0.44% 4,554,977 $ 142.707M Nov 16, 2026
SCDS 0.35% 1,071 $ 31.959K Nov 17, 2026
RESM 0.34% 442 $ 12.606K Jun 30, 2026
FESM 0.33% 667,036 $ 19.024M Jun 30, 2026
OASC 0.33% 10,264 $ 307.509K Aug 31, 2026
RUSC 0.29% 8,171 $ 233.037K Jun 30, 2026
FYEE 0.27% 19,102 $ 596.364K Jul 31, 2026
AVLV 0.21% 1,556,137 $ 48.754M Nov 16, 2026
FELG 0.21% 409,545 $ 11.68M Jun 30, 2026
CLSE 0.21% 61,799 $ 1.851M Aug 31, 2026
FHEQ 0.21% 61,010 $ 1.905M Jul 31, 2026
FMDE 0.20% 518,932 $ 14.8M Jun 30, 2026
AVMV 0.20% 53,972 $ 1.691M Nov 16, 2026
SEIS 0.17% 34,450 $ 982.514K Jun 30, 2026
DFAS 0.16% 1,684,662 $ 53.808M Nov 12, 2026
GVLU 0.15% 12,683 $ 397.358K Nov 17, 2026
AVIE 0.13% 690 $ 21.618K Nov 16, 2026
AVUQ 0.13% 18,239 $ 571.428K Nov 16, 2026
AVMC 0.12% 21,054 $ 659.622K Nov 16, 2026
FSML 0.11% 4,813 $ 137.267K Jun 30, 2026
FEAC 0.10% 897 $ 25.582K Jun 30, 2026
AVSU 0.08% 12,917 $ 404.69K Nov 16, 2026
FELC 0.07% 205,672 $ 5.866M Jun 30, 2026
VFMO 0.07% 45,887 $ 1.375M Aug 31, 2026
MKTN 0.06% 2,236 $ 63.771K Jun 30, 2026
AVUS 0.05% 228,267 $ 7.152M Nov 16, 2026
AVLC 0.05% 27,665 $ 866.744K Nov 16, 2026
DFSU 0.05% 34,115 $ 1.09M Nov 12, 2026
IALT short -0.04% -93,817 $ -2.939M Nov 16, 2026
MSSM 0.04% 8,856 $ 265.326K Aug 31, 2026
JSTC 0.03% 2,647 $ 82.931K Nov 17, 2026
DXUV 0.03% 56,666 $ 1.81M Nov 12, 2026
DFAC 0.02% 643,770 $ 20.562M Nov 12, 2026
DFAU 0.02% 61,211 $ 1.955M Nov 12, 2026
DFUS 0.01% 87,792 $ 2.804M Nov 12, 2026
DCOR 0.01% 105,240 $ 3.361M Nov 12, 2026